ArticleCPT: pharmacometrics & systems pharmacology2025
Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors.
Shengnan Du et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.